JP2005053907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005053907A5 JP2005053907A5 JP2004223680A JP2004223680A JP2005053907A5 JP 2005053907 A5 JP2005053907 A5 JP 2005053907A5 JP 2004223680 A JP2004223680 A JP 2004223680A JP 2004223680 A JP2004223680 A JP 2004223680A JP 2005053907 A5 JP2005053907 A5 JP 2005053907A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- epinastine
- pharmaceutical
- pharmaceutical composition
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 22
- 229960003449 epinastine Drugs 0.000 claims description 20
- 208000017520 skin disease Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000002552 dosage form Substances 0.000 claims description 13
- -1 diphenylpyralin Chemical compound 0.000 claims description 9
- 238000011200 topical administration Methods 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 208000003251 Pruritus Diseases 0.000 claims description 6
- 229960002548 epinastine hydrochloride Drugs 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 229960001340 histamine Drugs 0.000 claims 8
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical group C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 claims 4
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 claims 4
- 229960000428 carbinoxamine Drugs 0.000 claims 4
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims 4
- 229960003291 chlorphenamine Drugs 0.000 claims 4
- 229960000520 diphenhydramine Drugs 0.000 claims 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims 2
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 claims 2
- 206010040880 Skin irritation Diseases 0.000 claims 2
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims 2
- 229960003790 alimemazine Drugs 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 229960004574 azelastine Drugs 0.000 claims 2
- 229960002071 bepotastine Drugs 0.000 claims 2
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 claims 2
- 229960001803 cetirizine Drugs 0.000 claims 2
- 229960002881 clemastine Drugs 0.000 claims 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims 2
- 229960001140 cyproheptadine Drugs 0.000 claims 2
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims 2
- 229960001971 ebastine Drugs 0.000 claims 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims 2
- 229960000325 emedastine Drugs 0.000 claims 2
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 claims 2
- 229960003592 fexofenadine Drugs 0.000 claims 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 2
- 229960004958 ketotifen Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960005042 mequitazine Drugs 0.000 claims 2
- 229960004114 olopatadine Drugs 0.000 claims 2
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims 2
- 229960002698 oxatomide Drugs 0.000 claims 2
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 claims 2
- 229960003910 promethazine Drugs 0.000 claims 2
- 230000036556 skin irritation Effects 0.000 claims 2
- 231100000475 skin irritation Toxicity 0.000 claims 2
- 229960000351 terfenadine Drugs 0.000 claims 2
- 229960003223 tripelennamine Drugs 0.000 claims 2
- 229960001128 triprolidine Drugs 0.000 claims 2
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000006208 topical dosage form Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03016681 | 2003-08-01 | ||
| EP03016681.3 | 2003-08-01 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005053907A JP2005053907A (ja) | 2005-03-03 |
| JP2005053907A5 true JP2005053907A5 (https=) | 2007-09-13 |
| JP5021155B2 JP5021155B2 (ja) | 2012-09-05 |
Family
ID=34354409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004223680A Expired - Lifetime JP5021155B2 (ja) | 2003-08-01 | 2004-07-30 | エピナスチンと１種以上のさらなる抗−ｈ１−ヒスタミン類との組合せを含む皮膚疾患治療用製薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5021155B2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008148573A2 (de) * | 2007-06-08 | 2008-12-11 | Bayer Consumer Care Ag | Arzeimittel mit einer wirkstoffkombination enthaltend pantothensäure oder deren derivate zur behandlung von allergischen symptomen |
| JP2019043853A (ja) * | 2017-08-30 | 2019-03-22 | 旭化成株式会社 | 経皮吸収促進剤、経皮吸収促進助剤、及び経皮製剤 |
| WO2022138826A1 (ja) * | 2020-12-24 | 2022-06-30 | 参天製薬株式会社 | エピナスチン又はその塩を含有する塗布投与用医薬組成物 |
| CN116744904A (zh) * | 2020-12-24 | 2023-09-12 | 参天制药株式会社 | 含有依匹斯汀或其盐和硫系抗氧化剂的经皮施予用医药组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4563522B2 (ja) * | 1999-02-19 | 2010-10-13 | 豊也 加藤 | アレルギー疾患治療剤 |
| PE20020324A1 (es) * | 2000-10-06 | 2002-06-18 | Boehringer Ingelheim Int | Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina |
| US6827946B2 (en) * | 2001-12-05 | 2004-12-07 | Collegium Pharmaceutical, Inc. | Compositions containing both sedative and non-sedative antihistamines |
-
2004
- 2004-07-30 JP JP2004223680A patent/JP5021155B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2226435T3 (es) | Metodos de uso y composiciones que comprenden inhibidores de la recaptacion de dopamina. | |
| ES2329971T3 (es) | Composicion farmaceutica para la liberacion controlada de paracetamol. | |
| US11813247B2 (en) | NK-1 antagonist compositions and methods for use in treating depression | |
| US12521374B1 (en) | Combination therapy for a dopamine agonist | |
| TW200418474A (en) | Method of treating post-operative nausea and vomiting | |
| AU2008259864B2 (en) | Methods and compositions for administration of Oxybutynin | |
| RU2005122403A (ru) | Композиции нестероидных противовоспалительных лекарственных средств, противозастойных средств и антигистаминов | |
| JP2006515299A5 (https=) | ||
| CA3071377C (en) | Compositions and methods for improving muscle weakness in patients suffering from myasthenia gravis and other myasthenic syndromes | |
| CA2846340A1 (en) | Treatment of symptoms associated with female gastroparesis | |
| JP2005053907A5 (https=) | ||
| JP2008100924A (ja) | 総合感冒薬組み合わせ製剤 | |
| M Farber et al. | Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson’s disease | |
| US10610507B2 (en) | Methods for the treatment of sialorrhea | |
| US20250134903A1 (en) | Compositions and methods for treating pain | |
| JP2004026810A (ja) | 鼻炎用組成物 | |
| TW200906406A (en) | Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions | |
| HK40014066A (en) | Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions |